Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

The Weill Cancer Hub East has been established to explore the “interplay” between nutrition and immunotherapy in cancer ...

The FDA has approved GSK’s Blujepa for treating uncomplicated urinary tract infections (uUTIs) in adult females and ...

A total of 29 new blockbuster-in-waiting drugs entered the late-stage pipeline in 2024, a jump from the previous year’s 19.

Genmab has received approval from Japan's Ministry of Health, Labour and Welfare for its Tivdak to treat cervical cancer.

MSD has received approval from the EC for Capvaxive, a pneumococcal 21-valent conjugate vaccine, to prevent invasive disease ...

While Cassava is stopping investigations into simufilam in Alzheimer’s disease, the therapy is now being evaluated in ...

Sanofi will commence a Phase I/II trial with its vaccine candidate in the next few days to start generating immunogenicity ...

EU member states are set to launch the EU Health Data Space Regulation for harmonised data transfer on 26 March.

Tribune has secured $39.9m in seed and Series A funding for its therapy portfolio aimed at the central drivers of scar tissue ...

MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.

Valneva will work with local health authorities and wholesalers on the French island territory to distribute the vaccines.